Testosterone treatment should be considered in women with iatrogenic POI to manage hypoactive sexual desire disorder when other biopsychosocial aetiologies are excluded.	STRONG ⊕⊕◯◯
Testosterone treatment could be considered in women with non-iatrogenic POI to manage hypoactive sexual desire disorder when other biopsychosocial aetiologies are excluded.	CONDITIONAL ⊕⊕◯◯
HCPs should be aware that although short-term treatment with transdermal testosterone at doses approximating physiological premenopausal levels is safe, longer term safety data are lacking.	STRONG ⊕⊕◯◯
The guideline group recommends that women with POI are informed that there are limited data for androgen treatment for indications other than hypoactive sexual desire disorder, and that long-term health effects are unknown.	GPP